Online citations, reference lists, and bibliographies.
← Back to Search

Radiotherapy For The Treatment Of Pain In Malignant Pleural Mesothelioma: A Systematic Review.

N. Macleod, A. Price, N. O’Rourke, M. Fallon, B. Laird
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Radiotherapy is commonly used to treat pain in malignant pleural mesothelioma (MPM). The purpose of this systematic review is to examine the evidence for this practice. Medline (1946-2013), Embase (1974-2013) and Central (The Cochrane Library Issue 9, 2012) databases were searched. Eligible studies met the following criteria: MPM (histological or radiological diagnosis), radiotherapy given with the intent of improving pain, response rates to radiotherapy reported, dose and fractionation reported and the relationship between radiotherapy and pain response explored. All studies had independent review and were graded according to evidence level. Eight studies met the eligibility criteria. Two studies were prospective single arm phase II studies while the remainder were retrospective case series. All were graded as either Level 2 or Level 3 evidence. Due to marked heterogeneity among studies, quantitative synthesis of results was not possible. No high quality evidence currently exists to support radiotherapy in treating pain in MPM. Studies focusing on clear pain endpoints and improving target delineation are needed. Such studies should also use modern radiotherapy techniques and concentrate on dose escalation.
This paper references
10.3816/CLC.2009.n.033
Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma.
Brad E Wilcox (2009)
Awaiting Publication Pain in malignant pleural mesothelioma: a prospective characterisation study
C Bray (2016)
10.1016/j.pain.2009.02.007
Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2)
R. Dworkin (2009)
10.1200/JCO.2006.09.5281
Palliative radiotherapy trials for bone metastases: a systematic review.
E. Chow (2007)
10.1016/S1470-2045(08)70077-9
The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial
S. Bentzen (2008)
10.1111/J.1440-1673.1994.TB00177.X
Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation.
S. Davis (1994)
10.1201/b10448-105
Computed Tomography, Positron Emission Tomography, and Magnetic Resonance Imaging
Todd Pawlicki (2010)
10.2967/jnumed.114.142596
Variability and Uncertainty of 18F-FDG PET Imaging Protocols for Assessing Inflammation in Atherosclerosis: Suggestions for Improvement
Pauline Huet (2015)
10.1016/J.EPSC.2015.09.002
Malignant pleural mesothelioma in a child
Jed Brendan Scharf (2015)
10.1016/S0022-5223(19)40189-X
Malignant pleural mesothelioma. Report of 19 cases.
J. Shearin (1976)
10.1191/026921699671260095
Screening for psychiatric illness in the palliative care inpatient setting: a comparison between the Hospital Anxiety and Depression Scale and the General Health Questionnaire-12
P. Le Fevre (1999)
Lake, Advances in malignant mesothelioma
B. W. Robinson (2005)
10.1136/thx.2007.081430
Population based epidemiology and prognosis of mesothelioma in Leeds, UK
A. Chapman (2008)
10.1016/S0304-3959(00)00482-6
The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs
M. Bennett (2001)
[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].
H. Watanabe (2009)
10.1136/THX.54.3.238
Percutaneous cervical cordotomy for the control of pain in patients with pleural mesothelioma.
M. B. Jackson (1999)
10.1183/09031936.96.09122565
Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study.
C. J. Lindén (1996)
10.1016/J.RADONC.2004.09.017
Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05).
D. Roos (2005)
10.1016/S0140-6736(08)60727-8
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
10.1016/S0022-5223(03)00207-1
Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
R. Flores (2003)
10.1056/NEJM199904153401502
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
P. Rose (1999)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/S0360-3016(98)00409-X
Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura--a single-institution experience with 189 patients.
L. de Graaf-Strukowska (1999)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1016/0304-3959(75)90044-5
The McGill Pain Questionnaire: Major properties and scoring methods
R. Melzack (1975)
10.1016/S0167-8140(03)00006-9
International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases.
E. Chow (2002)
10.1016/0304-3959(87)91074-8
The short-form McGill pain questionnaire
R. Melzack (1987)
oncology 1): a randomised trial
Valko (2008)
10.1016/j.ijrobp.2009.06.037
Radiotherapy in malignant pleural mesothelioma.
M. McAleer (2009)
10.1016/S0360-3016(02)04147-0
Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases.
J. Wu (2003)
10.1191/026921699670764204
The use of interpleural analgesia using bupivacaine for pain relief in advanced cancer
B. Amesbury (1999)
10.1700/1088.11932
Effects of combined therapies on the survival of pleural mesothelioma patients treated in Brescia, 1982-2006.
P. Barbieri (2012)
Radiotherapy for the treatment of pain in malignant pleural mesothelioma: A systematic review
N MacLeod (2013)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1378/chest.32.3.340
Malignant mesothelioma of the pleura.
A. Tramujas (1957)
10.1016/S0169-5002(12)70070-3
69 PIT: A phase III trial of prophylactic irradiation of tracks in patients with malignant pleural mesothelioma following invasive chest wall intervention
N. Bayman (2009)
10.1097/JTO.0000000000000499
Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial
N. Macleod (2015)
10.1177/0269216307076398
Which measurement scales should we use to measure breathlessness in palliative care? A systematic review
S. Dorman (2007)
10.1158/0008-5472.CAN-09-4099
Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics.
X. Feng (2010)
10.1007/s00259-006-0252-x
Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer
U. Nestle (2006)
F-18 FDG PET-CT versus standard CT in radiotherapy planning in malignant pleural mesothelioma; an exploratory study
N MacLeod (2015)
10.1097/PPO.0b013e31820a7f80
Stereotactic Ablative Radiation Therapy for Primary Lung Tumors
J. Heinzerling (2011)
10.1097/JTO.0b013e3181c0a7ff
Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related Benign Pleural Disease: An Observational Pilot Study
H. Yildirim (2009)
10.1016/J.LUNGCAN.2005.03.013
Chemotherapy for malignant mesothelioma.
P. Baas (2005)
10.1007/s11307-009-0203-6
Prognostic Value of 18F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma
S. Lee (2009)
10.1200/JCO.2008.19.8523
Malignant pleural mesothelioma.
A. Tsao (2009)
Hypofractionated radiation therapy for prostate cancer: risks and potential benefits in a fiscally conservative health care system.
Sanjay Aneja (2012)
10.1016/S0360-3016(02)02989-9
Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15).
A. Bezjak (2002)
10.1007/s00520-010-0961-3
Characterization of cancer-induced bone pain: an exploratory study
B. Laird (2010)
10.1016/J.LUNGCAN.2005.03.031
Inverse planned stereotactic intensity modulated radiotherapy (IMRT) in the palliative treatment of malignant mesothelioma of the pleura: the Heidelberg experience.
M. Muenter (2005)
10.1016/S0025-6196(12)65411-1
Malignant mesothelioma of the pleura.
R. J. Pisani (1988)
10.1200/JCO.2007.11.8497
Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy.
O. Riesterer (2007)
10.1200/JCO.2005.03.3027
Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
A. Bottomley (2006)
10.1016/S0936-6555(05)80582-5
The role of palliative radiotherapy in malignant mesothelioma.
D. Bissett (1991)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1136/thx.39.4.255
Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients.
M. Law (1984)
10.1016/j.ejpain.2011.05.002
Quantitative Sensory Testing to assess the sensory characteristics of cancer‐induced bone pain after radiotherapy and potential clinical biomarkers of response
A. Scott (2012)
10.1016/S0167-8140(01)00470-4
Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET).
Y. Erdi (2002)
10.1016/0360-3016(82)90379-0
Radiation therapy in the management of patients with mesothelioma.
W. Gordon (1982)
10.1097/00000421-199002000-00002
The Treatment of Malignant Mesothelioma of the Pleura: Review of a 5‐Year Experience, With Special Reference to Radiotherapy
D. Ball (1990)
10.1016/j.ejca.2011.05.012
Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma.
P. Jenkins (2011)
10.1007/978-0-387-88441-7_26
[Pleural mesothelioma].
A. DE GASPERIS (1950)
10.1016/0022-3999(93)90081-P
Development of a fatigue scale.
T. Chalder (1993)
Pain assessment: global use of the Brief Pain Inventory.
C. Cleeland (1994)
10.1007/s00701-002-0945-2
CT-Guided Percutaneous Selective Cordotomy for Treatment of Intractable Pain in Patients with Malignant Pleural Mesothelioma
Y. Kanpolat (2002)
10.1245/s10434-010-1107-z
Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications
H. Lee (2010)
10.1097/00002508-200409000-00005
Validity of the Brief Pain Inventory for Use in Documenting the Outcomes of Patients With Noncancer Pain
S. Keller (2004)
10.1016/J.LUNGCAN.2004.04.026
Radiation therapy of mesothelioma: the Heidelberg experience and future aspects.
D. Zierhut (2004)
10.5055/JOM.2012.0091
Palliative care in the management of lung cancer: analgesic utilization and barriers to optimal pain management.
C. Simone (2012)
10.2214/AJR.10.4923
A systematic review of the factors affecting accuracy of SUV measurements.
Michael C. C. Adams (2010)
Mesothelioma: treatment and survival of a patient population and review of the literature.
J. Stathopoulos (2005)
An updated literature review
L Vedana (2002)
10.1200/JCO.2003.01.008
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.
D. Adelstein (2003)
10.3779/j.issn.1009-3419.2010.01.10
Analysis of the Effect of Radiotherapy on Malignant Pleural Mesothelioma when Given on Adjuvant or Palliative Basis
Hesham A El Hossieny (2010)
10.1016/S0169-5002(02)00180-0
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1634/theoncologist.2010-0185
What is the role of radiotherapy in malignant pleural mesothelioma?
A. Price (2011)
10.1016/S0304-3959(99)00006-8
Breakthrough pain: characteristics and impact in patients with cancer pain
R. Portenoy (1999)
10.1016/j.lungcan.2009.04.015
Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma.
P. Veit-Haibach (2010)



This paper is referenced by
10.1016/B978-0-12-803523-8.00014-9
Site-Specific Symptom Management: Palliative Radiotherapy for Advanced and Metastatic Lung Cancer
R. Rhome (2017)
10.1055/s-0039-1693406
Malignant Mesothelioma: Has Anything Changed?
Roger Y Kim (2019)
10.1016/S1877-1203(16)30135-5
Traitement du mésothéliome pleural malin en 2016
Arnaud Scherpereel (2016)
10.1016/J.LUNGCAN.2019.03.023
The role of radiation treatment in pleural mesothelioma: Highlights of the 14th International Conference of the International mesothelioma interest group.
R. MacRae (2019)
10.1007/978-3-319-52619-5_36-1
Radiation Therapy in Mesothelioma
J. Willmann (2019)
10.12816/0042979
A Retrospective Analysis of Epidemiology Prognostic Factor and Response of Treatment of Malignant Pleural Mesothelioma
Dalia Abd El-Ghany El-Khodary (2018)
10.1097/JTO.0000000000000499
Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial
N. Macleod (2015)
10.1136/esmoopen-2019-000669
How I treat malignant pleural mesothelioma
G. Viscardi (2020)
10.1080/14656566.2016.1176145
Advances in treatment of mesothelioma
C. Maggioni (2016)
10.2147/LCTT.S192558
Pain management in patients with malignant mesothelioma: challenges and solutions
J. Saunders (2019)
10.1016/j.lungcan.2015.05.014
Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England.
R. Damhuis (2015)
10.17795/RRO-3999
F-18 FDG PET-CT Influences Target Delineation When Combined With Standard CT-Based Radiotherapy Planning in the Palliative Setting in Malignant Pleural Mesothelioma; an Exploratory Study
Nicholas Mac Leod (2015)
Malignant pleural mesothelioma: ESMOClinical Practice Guidelines for diagnosis, treatment and follow-up†
P. Baas (2015)
10.1188/17.CJON.S3.54-70
Nonpharmacologic Pain Interventions: A review of evidence‐based practices for reducing chronic cancer pain
L. Eaton (2017)
10.1136/thoraxjnl-2017-211321
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
I. Woolhouse (2018)
10.12968/hmed.2015.76.7.384
Medical and oncological management of malignant mesothelioma.
A. Bibby (2015)
10.1007/174_2017_27
Lung Cancer and Other Thoracic Malignancies
M. Harkenrider (2017)
10.1007/978-3-030-16884-1_14
Role of Radiotherapy in Malignant Pleural Mesothelioma
M. Scorsetti (2019)
10.1111/1754-9485.12312
Hemithoracic radiation therapy after extrapleural pneumonectomy for malignant pleural mesothelioma: Applicable to all and by all?
R. Haas (2015)
10.1002/14651858.CD012605.pub2
Radical multimodality therapy for malignant pleural mesothelioma.
O. Abdel-Rahman (2018)
Using Radiotherapy to Treat Pain in Mesothelioma
Nicholas Macleod (2015)
SYNDECAN-1 INSIGHTS IN MESOTHELIOMA THESIS FOR DOCTORAL DEGREE ( Ph . D . ) By Ghazal
Heidari Hamedani (2017)
10.12968/hmed.2017.78.4.219
Palliative care for patients with mesothelioma.
Marianne Tinkler (2017)
10.1111/1754-9485.12636
High‐dose palliative radiotherapy for malignant pleural mesothelioma
F. Foroudi (2017)
10.1016/j.rmed.2017.11.015
Progress and challenges in Mesothelioma: From bench to bedside.
K. Blyth (2018)
10.1016/j.ctro.2017.11.004
SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma
M. Ashton (2018)
PROGRESS AND CHALLENGES IN MESOTHELIOMA: FROM BENCH TO BEDSIDE Authors
K. Blyth (2017)
10.1016/j.lungcan.2015.03.013
Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma.
R. Cornelissen (2015)
10.1007/978-3-319-53560-9_14
Radiotherapy and Photodynamic Therapy for Malignant Pleural Mesothelioma
C. Simone (2017)
Semantic Scholar Logo Some data provided by SemanticScholar